✦ LIBER ✦

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer

✍ Scribed by Emmanuel S. Antonarakis, Elisabeth I. Heath…

Book ID: 120776611
Publisher: Springer
Year: 2013
Tongue: English
Weight: 545 KB
Volume: 71
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-013-2079-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of lapatinib, a dual EG

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

✍ Whang, Young E.; Armstrong, Andrew J.; Rathmell, W. Kimryn; Godley, Paul A.; Kim 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 220 KB

P114 Safety and efficacy of orteronel (T

P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study

✍ Petrylak, D.; Gandhi, J.; Clark, W.R.; Heath, E.I.; Lin, J.; Oh, W.K.; Agus, D.B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A phase 2 study of estramustine, docetax

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer : Results from Cancer and Leukemia Group B Study 90006

✍ Joel Picus; Susan Halabi; W. Kevin Kelly; Nicholas J. Vogelzang; Young E. Whang; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

A phase 2 study of oral MKC-1, an inhibi

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

✍ Jason E. Faris, Jamie Arnott, Hui Zheng, David P. Ryan, Thomas A. Abrams, Lawren 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 169 KB

A Randomized, Double-Blind, Dose-Finding

A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer

✍ Christopher C. Parker; Sarah Pascoe; Aleš Chodacki; Joe M. O'Sullivan; Josep R. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 930 KB

124 Activity and safety of the investiga

124 Activity and safety of the investigational agent orteronel (ortl, TAK-700) in men with nonmetastatic castration-resistant prostate cancer (CRPC) and rising prostate-specific antigen (PSA): Results of a phase 2 study

✍ M. Hussain; P. Corn; D. Michaelson; H. Hammers; J. Alumkal; C. Ryan; J. Bruce; S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 73 KB